Drug Shortage Report for TEVA-BUPROPION XL
| Report ID | 120473 |
| Drug Identification Number | 02439662 |
| Brand name | TEVA-BUPROPION XL |
| Common or Proper name | BUPROPION XL 300MG SR TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | BUPROPION HYDROCHLORIDE |
| Strength(s) | 300MG |
| Dosage form(s) | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL ORAL |
| Packaging size | 500 |
| ATC code | N06AX |
| ATC description | ANTIDEPRESSANTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2020-07-15 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-29 |
| Shortage status | Resolved |
| Updated date | 2021-09-30 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.